|
Visionary Panelists See Different Trends, Treatment Approaches
| |
 |
|
|
| |
Daniel Kopans, MD, and Monica Morrow, MD, participate in the Visionary Panel discussion Breast Cancer Management in 5 Years. |
|
|
Joking that “some people confuse ‘visionary’ with hallucination,” Daniel Kopans, MD, joined four other experts in predicting the status of breast cancer treatment and research in the next five years.
The noon Visionary Panel was moderated by MBCC Course Director Daniel A. Osman, MD, and included Kopans, professor of radiology, Massachusetts General Hospital, Boston; Lance Liotta, MD, PhD, professor of life sciences, co-director, Center for Applied Proteomics and Molecular Medicine, Department of Molecular and Microbiology, George Mason University, Manassas, VA; Soon Myung Paik, MD, director, division of pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh; Monica Morrow, MD, chairman, department of surgical oncology, Fox Chase Cancer Center, Philadelphia; and George Sledge Jr., MD, professor of medicine and pathology, Ballvé-Lantero professor of oncology, Indiana University School of Medicine, Eastern Cooperative Oncology Group, Indianapolis.
Kopans said medical professionals have “almost reached the point in imaging where everything we can imagine can pretty much be done.” In the future, he envisions more studies concentrating on multimodality early detection, including 3-D x-ray mammograms, and more exploration into nuclear medicine such as electrical impedance and optical imaging. ...
Read more in the PDF version of MBCC News
Experts Argue for Selectivity in Targeting Tumors, Reducing Overtreatmentand
A group of experts in the field of early breast cancer detection and therapy presented intellectual insights at the beginning of yesterday’s morning program. The first speaker was Lance Liotta, MD, PhD, professor of life sciences, co-director, Center for Applied Proteomics and Molecular Medicine Department of Molecular and Microbiology, George Mason University, Manassas, VA. He asked whether molecular markers can predict which DCIS cases will recur.
“Many molecular and genetic changes occur in the breast microenvironment, way before we get to the carcinoma stage,” said Liotta. “At the molecular level, many changes have already taken place that indicate invasive potential.” ...
Read more in the PDF version of MBCC News
Join Us at 12:15 pm Today for the MBCC “Award of Excellence” Presentation
 |
|
|
|
| Larry Norton, MD |
|
|
|
The Miami Breast Cancer Conference will present its annual Award of Excellence to Larry Norton, MD, deputy physician-in-chief for breast cancer programs at the Memorial Sloan-Kettering Cancer Center in New York. The award will be presented at 12:15 p.m. today following the morning sessions.
Norton’s highly regarded research concerns the basic biology of cancer, the mathematics of tumor causation and growth, and the development of approaches to better diagnosis, prevention, and drug treatment of the disease.
“The award is given to an outstanding contributor to the management and research of breast cancer,” said MBCC founder Daniel Osman, MD. “Dr. Norton has been a world leader in the advancement of the management of breast cancer for many years. He has the compassion and depth that make him such a leader.”
Among Norton’s research topics are the molecular identification of genes that predispose people to cancer or otherwise cause cancer, the development of new drugs, monoclonal antibodies that target growth factor receptors, and vaccines. ...
Read more in the PDF version of MBCC New
This issue of MBCC News is sponsored by Agendia.
|
